- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07933042
A Study of Urine Volatile Organic Compounds for Disease Detection (TOBY ATLAS)
TOBY ATLAS: A Multi-Site, Non-Interventional Study of Urinary Volatile Organic Compounds
The goal of this observational study is to develop and evaluate urine tests for detecting disease in adults. It will initially focus on prostate, bladder, and kidney cancer. Researchers will compare urine samples and medical records from people with and without these diseases to see whether the tests can detect them accurately. Participants may provide a urine sample during a routine visit. Study results will not be returned to participants or used in their care.
Обзор исследования
Статус
Условия
Подробное описание
TOBY ATLAS is a multi-center master protocol that supports the development and validation of urine-based tests for screening, diagnosis, and monitoring of multiple diseases. The study uses prospectively collected, residual, banked, and purchased urine samples, where permitted.
Researchers will analyze urine for volatile organic compounds using gas chromatography-mass spectrometry and develop models using samples with known disease status. Each model will be locked before it is evaluated using a separate set of blinded samples.
Disease status and available standard-of-care test results will be obtained from medical records. Researchers may also review records over time to identify later diagnoses or outcomes. Sites and diseases may be added as the study progresses.
Тип исследования
Регистрация (Оцененный)
Контакты и местонахождение
Контакты исследования
- Имя: TOBY ATLAS Study Team
- Номер телефона: 309-592-8898
- Электронная почта: info@toby.health
Учебное резервное копирование контактов
- Имя: TOBY ATLAS Study Team
- Электронная почта: press@toby.health
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Adults with target diseases and comparison participants, including healthy volunteers and individuals with other diseases, benign conditions, or negative diagnostic work-ups. Participants are identified through routine care and other permitted specimen sources.
Описание
Inclusion Criteria:
- Age 50 years or older, or another age range set in the applicable disease specification (for example, 45 or older for colorectal cancer).
- Informed consent, or eligibility under an exemption or waiver for waste, residual, banked, or purchased specimens.
- Medical records available for the reference standard.
- Meets the case or control definition and other inclusion criteria in at least one disease specification, or belongs to the Healthy Control Set.
Exclusion Criteria:
- Any exclusion stated in the applicable disease specification.
- Symptomatic urinary tract infection at collection, unless enrolled as a confounder control.
- Current pregnancy, imprisonment, or inability to consent for oneself (consented route).
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: CASE_CONTROL
- Временные перспективы: PROSPECTIVE
Когорты и вмешательства
Группа / когорта |
|---|
|
Target disease cases
Participants with a target disease established by the applicable reference standard, including participants assessed after treatment where specified. |
|
Controls
Participants without the target disease for a given analysis, including healthy participants and participants with other diseases, benign conditions, or negative diagnostic work-ups. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Clinical performance of each locked assay
Временное ограничение: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Sensitivity and specificity at pre-specified thresholds, and area under the receiver operating characteristic curve, of each locked assay against the applicable reference standard in its intended-use population, using blinded validation specimens not used to develop that assay. Estimates will include 95% confidence intervals. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
|
Paired comparison with available standard-of-care tests
Временное ограничение: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Differences in sensitivity, specificity, and area under the receiver operating characteristic curve between each locked assay and each available standard-of-care test in the same participants, with 95% confidence intervals. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Assay performance by subgroup and signal origin
Временное ограничение: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Sensitivity, specificity, and area under the receiver operating characteristic curve across thresholds and by disease characteristics, populations, and control types, including stage, grade, and age; accuracy of signal-origin classification. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
|
Protocol-conforming specimens with final reference-standard classification
Временное ограничение: From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.
|
Number of protocol-conforming urine specimens with final reference-standard classification, summarized by disease and control type. |
From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Candidate assays advanced to validation
Временное ограничение: From study start through study completion, estimated up to 5 years
|
Number of candidate assays developed using the Development Pool that are locked and carried forward to a Validation Plan. |
From study start through study completion, estimated up to 5 years
|
|
Exploratory prognostic and simulated clinical and economic outcomes
Временное ограничение: Up to 5 years after specimen collection, where follow-up is permitted and available
|
Where optional medical-record follow-up is available, compare progression, recurrence, treatment response, stage at diagnosis, procedures, health care use, and costs with blinded assay predictions. These are exploratory prognostic and simulated health-economic analyses; test results are not used in care. |
Up to 5 years after specimen collection, where follow-up is permitted and available
|
Соавторы и исследователи
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- TOBY-ATLAS-001
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
There is currently no plan to make individual participant data available to other researchers.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .